Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients

This study has been completed.
Information provided by (Responsible Party):
ROX Medical, Inc. Identifier:
First received: January 28, 2009
Last updated: January 27, 2015
Last verified: January 2015
To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Device: Arteriovenous Fistula (ROX AC1)
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study of the Effect of the ROX Percutaneous Arteriovenous Fistula System (ROX AC1) on Exercise Capacity and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:

Further study details as provided by ROX Medical, Inc.:

Primary Outcome Measures:
  • Improvement in exercise capacity. [ Time Frame: 12 weeks post-procedure ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improvement in quality of life. [ Time Frame: 12 weeks post-procedure ] [ Designated as safety issue: No ]

Enrollment: 46
Study Start Date: November 2008
Study Completion Date: November 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental: Group A Anastomotic Coupler
Device: ROX Anastomotic Coupler System (ACS). The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
Device: Arteriovenous Fistula (ROX AC1)
The percutaneous creation of an arteriovenous fistula.

Detailed Description:
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that leads to irreversible changes in the lung structure, but also to systemic changes in the body that can influence the severity of the disease. The irreversible changes to the lungs can be seen in limitations in the pulmonary function. The purpose of this clinical investigation is to evaluate the performance and efficacy of the ROX AC1 on exercise capacity and respiratory quality of life.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of advanced Chronic Obstructive Pulmonary Disease (COPD) must be made on the basis of current findings, medical history and physical examination.

Exclusion Criteria:

  • Subject not qualifying because of physical or psychological condition that may put them at risk of participating.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00832611

Universitätsklinikum Gieβen und Marburg, Standort Marburg
Marburg, Germany, D-35043
Sponsors and Collaborators
ROX Medical, Inc.
Principal Investigator: Claus Vogelmeier, MD Universitätsklinikum Gieβen und Marburg, Standort Marburg
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: ROX Medical, Inc. Identifier: NCT00832611     History of Changes
Other Study ID Numbers: ROX IX
Study First Received: January 28, 2009
Last Updated: January 27, 2015
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by ROX Medical, Inc.:
Lung Disease
Chronic Airflow Obstruction
Chronic Bronchitis
Chronic Emphysema

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases processed this record on November 27, 2015